Back to Search
Start Over
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice
- Source :
- Virus Genes. 55:290-297
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Integrase-strand-transfer inhibitors (INSTIs) are known to rapidly reduce HIV-1 plasma viral load, replication cycles, and new viral integrations, thus potentially limiting viral evolution. Here, we assessed the role of INSTIs on HIV-1 V3 evolution in a cohort of 89 HIV-1-infected individuals starting an INSTI- (N = 41, [dolutegravir: N = 1; elvitegravir: N = 3; raltegravir: N = 37]) or a non-INSTI-based (N = 48) combined antiretroviral therapy (cART), with two plasma RNA V3 genotypic tests available (one before [baseline] and one during cART). V3 sequences were analysed for genetic distance (Tajima-Nei model) and positive selection (dN/dS ratio). Individuals were mainly infected by B subtype (71.9%). Median (interquartile-range, IQR) plasma viral load and CD4 + T cell count at baseline were 4.8 (3.5–5.5) log10 copies/mL and 207 (67–441) cells/mm3, respectively. Genetic distance (median, IQR) between the V3 sequences obtained during cART and those obtained at baseline was 0.04 (0.01–0.07). By considering treatment, genetic distance was significantly lower in INSTI-treated than in non-INSTI-treated individuals (median [IQR]: 0.03[0.01–0.04] vs. 0.05[0.02–0.08], p = 0.026). In line with this, a positive selection (defined as dN/dS ≥ 1) was observed in 36.6% of V3 sequences belonging to the INSTI-treated group and in 56.3% of non-INSTI group (p = 0.05). Multivariable logistic regression confirmed the independent correlation of INSTI-based regimens with a lower probability of both V3 evolution (adjusted odds-ratio: 0.35 [confidence interval (CI) 0.13–0.88], p = 0.027) and positive selection (even if with a trend) (adjusted odds-ratio: 0.46 [CI 0.19–1.11], p = 0.083). Overall, this study suggests a role of INSTI-based regimen in limiting HIV-1 V3 evolution over time. Further studies are required to confirm these findings.
- Subjects :
- Oncology
v3
hiv-1 evolution
HIV-1
HIV-1 evolution
HIV-1 tropism
Integrase inhibitors
V3
Drug Resistance
Integrase inhibitor
HIV Infections
hiv-1
HIV Integrase
HIV Envelope Protein gp120
Piperazines
chemistry.chemical_compound
Heterocyclic Compounds
Viral
0303 health sciences
Elvitegravir
General Medicine
Viral Load
Settore MED/07 - Microbiologia e Microbiologia Clinica
Drug Resistance, Viral
Evolution, Molecular
Genotype
Heterocyclic Compounds, 3-Ring
Humans
Peptide Fragments
Dolutegravir
Viral load
medicine.drug
Cart
medicine.medical_specialty
Pyridones
Evolution
Biology
3-Ring
hiv-1 tropism
molecular biology
genetics
virology
03 medical and health sciences
Virology
Internal medicine
Oxazines
Genetics
medicine
Molecular Biology
030304 developmental biology
030306 microbiology
Molecular
Raltegravir
Confidence interval
Regimen
chemistry
Subjects
Details
- ISSN :
- 1572994X and 09208569
- Volume :
- 55
- Database :
- OpenAIRE
- Journal :
- Virus Genes
- Accession number :
- edsair.doi.dedup.....f47f4590dac41d3d202fd02bdfc089bc